Skip to main content
Top
Published in: Journal of Gastroenterology 7/2009

01-07-2009 | Original Article—Alimentary Tract

Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer

Authors: Hideaki Shimada, Akiko Kagaya, Tooru Shiratori, Fumio Nomura, Masaki Takiguchi, Hisahiro Matsubara, Takaki Hiwasa

Published in: Journal of Gastroenterology | Issue 7/2009

Login to get access

Abstract

Background

Serological identification of antigens by recombinant cDNA expression cloning (SEREX) is an established method for detecting new tumor-specific antigens. Antibodies to SEREX antigens may be useful for the detection of esophageal squamous cell carcinoma (SCC).

Methods

A phage cDNA library of a human esophageal SCC cell line was screened using sera of patients with esophageal SCC. The presence and levels of serum antibodies to SEREX antigens were established by Western blotting and enzyme-linked immunosorbent assay (ELISA) using purified recombinant antigen proteins, respectively.

Results

The newly identified esophageal SCC antigen is encoded by a novel gene located on chromosome 1, here designated CUEC-23. Serum CUEC-23-antibodies (s-CUEC-23-Abs) were detected in 14 of 54 patients with esophageal SCC (26%) by Western blot analysis. Esophageal SCCs were positive for s-CUEC-23-Abs together with CEA, SCC-Ag or CYFRA21-1 in 44, 41 and 52% of cases, respectively. There was no detectable association between the presence of s-CUEC-23-Abs and clinicopathological variables. ELISA showed that the levels of s-CUEC-23-Abs were significantly higher in patients with esophageal SCC than in healthy volunteers (17% in the former using the mean + 3 SD of s-CUEC-23-Abs in healthy controls as the cutoff).

Conclusion

A new tumor antigen, CUEC-23, was identified by SEREX screening. s-CUEC-23-Abs might be a useful serum marker to detect esophageal SCC.
Literature
1.
go back to reference Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810–3.PubMedCrossRef Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810–3.PubMedCrossRef
2.
go back to reference Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914–8.PubMedCrossRef Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914–8.PubMedCrossRef
3.
go back to reference Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004;54:95–100.PubMedCrossRef Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004;54:95–100.PubMedCrossRef
5.
go back to reference Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRef Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRef
6.
go back to reference Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.PubMedCrossRef
7.
go back to reference Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, et al. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus. 2007;20:117–22.PubMedCrossRef Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, et al. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus. 2007;20:117–22.PubMedCrossRef
8.
go back to reference Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.PubMedCrossRef Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.PubMedCrossRef
9.
go back to reference Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005;26:77–86.PubMed Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005;26:77–86.PubMed
10.
go back to reference Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006;28:463–8.PubMed Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006;28:463–8.PubMed
11.
go back to reference Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum TRIM21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97:380–6.PubMedCrossRef Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum TRIM21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97:380–6.PubMedCrossRef
12.
go back to reference Hiwasa T, Shimada H, Ochiai T, Takiguchi M. Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma. In: Hiwasa T, editor. Moleculomics and thereafter. Kerala: Research Signpost; 2006. p. 99–117. Hiwasa T, Shimada H, Ochiai T, Takiguchi M. Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma. In: Hiwasa T, editor. Moleculomics and thereafter. Kerala: Research Signpost; 2006. p. 99–117.
13.
go back to reference Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, et al. Serum anti-myogegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007;30:97–103.PubMed Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, et al. Serum anti-myogegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007;30:97–103.PubMed
14.
go back to reference Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn.). Jpn J Oral Maxillofac Surg. 1990;36:307–16. Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn.). Jpn J Oral Maxillofac Surg. 1990;36:307–16.
15.
go back to reference Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley; 2000. Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley; 2000.
16.
go back to reference Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, et al. Significance of serum CYFRA21–1 in the patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196:573–8.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, et al. Significance of serum CYFRA21–1 in the patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196:573–8.PubMedCrossRef
17.
go back to reference Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, et al. Prognostic significance of serum SCC-Ag in the patients with esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, et al. Prognostic significance of serum SCC-Ag in the patients with esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.PubMedCrossRef
Metadata
Title
Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer
Authors
Hideaki Shimada
Akiko Kagaya
Tooru Shiratori
Fumio Nomura
Masaki Takiguchi
Hisahiro Matsubara
Takaki Hiwasa
Publication date
01-07-2009
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 7/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0060-8

Other articles of this Issue 7/2009

Journal of Gastroenterology 7/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.